Abstracts & publications

Radiotheranostic targeting of fPSA

Inter- and intraobserver agreement of the quantitative assessment of [99mTc]-labelled anti-programmed death-ligand 1 (PD-L1) SPECT/CT in non-small cell lung cancer

Why next generation radiopharmaceuticals will play a key role in the quest for precision medicine

Open Access Early Phase I Study of a 99mTc-Labeled Anti–Programmed Death Ligand-1 (PD-L1) Single-Domain Antibody in SPECT/CT Assessment of PD-L1 Expression in Non–Small Cell Lung Cancer

Targeted alpha therapy using short-lived alpha-particles and the promise of nanobodies as targeting vehicle

Radiolabeled nanobodies as theranostic tools in targeted radionuclide therapy of cancer

99mTc-Labeled Nanobodies: A New Type of Targeted Probes for Imaging Antigen Expression